PRMT1 and acute myeloid leukemia: In FLT3‐ITD mutant AML, genetic or pharmacological suppression of PRMT1 markedly decreases FLT3‐ITD methylation levels and improves the effectiveness of tyrosine kinase inhibitors in eradicating leukemia progenitor cells.